The penetrance of melanoma in families with CDKN2A pathogenic variants is estimated to range from 58 to 92% by age 80, and the penetrance of pancreatic cancer is estimated at 17–21% by age 70 [7] to 75 [5] in Western Countries. Here, CDKN2A is linked to melanoma.